All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
173 results
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Protocol No
HJKC3-0002
Sub Category
Hematologic/Blood Related Cancers
A Phase 2 Study of Lisocabragene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Agressive B-Cell NHL (017006)
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (Transcend-Pilot-017006)
Protocol No
JUNO-JCAR017-017006
Sub Category
Hematologic/Blood Related Cancers
Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL
YTB323 (CD19-specific CAR-T Cells) in patients with CLL/SLL and DLBCL
Protocol No
NOVARTIS-YTB323A12101
Sub Category
Hematologic/Blood Related Cancers
A Pilot Study of Zydelig in Patients with B-Cell Malignancies as Post-Autologous Transplant Remission Maintenance
Zydelig Maintenance in B-Cell Non-Hodkins Lymphoma after ASCT
Protocol No
UMARYLAND-1630GCC-ZYDELIG
Sub Category
Hematologic/Blood Related Cancers
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Protocol No
ECOG-EA9152
Sub Category
Hematologic/Blood Related Cancers
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Protocol No
ADCT-402-201-DLBCL
Sub Category
Hematologic/Blood Related Cancers
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab In Patients With Locoregionally Recurrent Or Second Primary Squamous Cell Cancer Of The Head And Neck
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Protocol No
WINSHIP-4221-17
Sub Category
Head and Neck Cancers
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer
Protocol No
SWOG-LUNGMAP
Sub Category
Thoracic Cancers
The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer
To assess how well the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer as measured by Overall Survival.
Protocol No
GOG-3018-VBL-VB-111-701
Sub Category
Gynecologic Cancers
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
To investigate the feasibility of administration of atezolizumab as an immune primer and concurrent with chemoradiation (CRT) therapy in patients with locally advanced cervical cancer
Protocol No
NRG-GY017
Sub Category
Gynecologic Cancers
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
The purpose of the study is to compare any good and bad effects of using a combination of the investigational agents cediranib and olaparib, to using the standard chemotherapy, or cediranib alone, or olaparib alone.
Protocol No
NRG-GY005
Sub Category
Gynecologic Cancers
JETStream AtheRectomy with Adjunctive Paclitaxel-Coated BallooN Angioplasty vs Balloon AnGioplasty followed by Paclitaxel-Coated Balloon in Treating ComplEx Denovo FemoRopopliteal Arterial Disease (JET-RANGER)
The purpose of the study is to assess the feasibility of treating peripheral arterial disease (PAD) with a drug coated balloon along with removal of the plaque using the JetStream XC atherectomy system when compared to a drug coated balloon only. Arteries are reassessed at 1 month, 6 months, 1 year, 2 year and 3 years after treatment.
Primary Investigator: Robert A. Hieb, MD, RVT, FSIR
Subinvestigators: Michael J. Malinowski, MD; Parag J. Patel, MD, MS; Peter J. Rossi, MD
ClinicalTrials.gov Identifier: NCT03206762
Status: Currently Enrolling
Sub Category
Vascular Surgery and Vascular Interventional Radiology
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer
Protocol No
NRG-GU006
Sub Category
Prostate and Urologic Cancers
A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma.
A Phase 1b-2, Open-Label Study of JNJ-68284528, a CAR-T Therapy Directed against BCMA in rrMM
Protocol No
JNJ-68284528MMY2001
Sub Category
Hematologic/Blood Related Cancers
A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-Versus-Host Disease (sr-aGvHD)
Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease
Protocol No
ABGENOMICS-2017-002-01
Sub Category
Hematologic/Blood Related Cancers